Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03246113 · ClinicalTrials.gov registry record · Phase 1
Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03246113 is a Phase 1 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 1 participants.
The verdict
NCT03246113, a Phase 1 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this single arm Phase I feasibility study is to investigate the tolerability of cannabis with concurrent chemoradiation in the treatment of glioblastoma multiforme (GBM). A strain of cannabis provided by The National Institute of Drug Abuse (NIDA) that has a high concentration of cannabidiol (CBD) and a low concentration of THC (relative to average street cannabis) will be tested in order to maximize clinical efficacy while minimizing intoxicating side effects in this medically-ill population.
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- DRUG Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2019-05-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03246113
The ClinicalTrials.gov registry entry for NCT03246113 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT03246113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03246113 about?
NCT03246113 is a clinical study titled "Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma". The goal of this single arm Phase I feasibility study is to investigate the tolerability of cannabis with concurrent chemoradiation in the treatment of glioblastoma multiforme (GBM). A strain of cannabis provided by The National Institute of Drug Abuse (NIDA) that has a high concentration of cannabi...
What is the current status of trial NCT03246113?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2018-03-19. Estimated completion is 2019-05-09.
What interventions are being tested in trial NCT03246113?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), Cannabis (DRUG).
Who is sponsoring clinical trial NCT03246113?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.